Discontinuation of Clonazepam in the Treatment of Social Phobia
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Patients with social phobia who responded well to 6 months of open-label treatment with clonazepam were assigned to receive either continuation treatment (CT) with clonazepam for another 5 months, or to undergo discontinuation treatment (DT) using a clonazepam taper at the rate of 0.25 mg every 2 weeks, with double-blind placebo substitution. Clinical efficacy was compared between the CT and DT groups using three different social phobia scales. Benzodiazepine withdrawal symptoms were also measured. Relapse rates were 0 and 21.1% in the CT and DT groups, respectively. Subjects in the CT group generally showed a more favorable clinical response at midpoint and/or endpoint, although even in the DT group clinical response remained good. With respect to withdrawal symptoms, the rates were low in both groups (12.5% for CT and 27.7% for DT) with no real evidence suggesting significant withdrawal difficulties. At the end of 11 months of treatment with clonazepam, however, a more rapid withdrawal rate was associated with greater distress. This study offers preliminary evidence to suggest that continuation therapy with clonazepam in the treatment of social phobia is safe and effective, producing a somewhat greater clinical benefit than a slow-taper discontinuation regime. However, even in the DT group, withdrawal symptoms were not found to be a major problem. The study can be taken as supportive of benefit for longterm clonazepam treatment in social phobia, as well as being compatible with a reasonably good outcome after short-term treatment and slow taper.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Clomipramine, Clonazepam, and Clonidine Treatment of Obsessive-Compulsive Disorder
HEWLETT, W. A., VINOGRADOV, S., & AGRAS, W. S. (1992) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199212000-00008 · Cited by 129
Cited by
Pande, A. C., Feltner, D. E., Jefferson, J. W., Davidson, J. R. T., Pollack, M., Stein, M. B., Lydiard, R. B., Futterer, R., Robinson, P., Slomkowski, M., et al. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000117423.05703.e7 · Cited by 227
Self-citationPharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Pharmacotherapy for social anxiety disorder (SAnD)
Williams, T., Hattingh, C. J., Kariuki, C. M., Tromp, S. A., van Balkom, A. J., Ipser, J. C., & Stein, D. J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001206.pub3 · Cited by 84
Walker, J. R., Van Ameringen, M. A., Swinson, R., Bowen, R. C., Chokka, P. R., Goldner, E., Johnston, D. C., Lavallie, Y.-J., Nandy, S., Pecknold, J. C., et al. (2000) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-200012000-00009 · Cited by 84
Pharmacotherapy of social phobia
Davidson, J. R. T. (2003) · Acta Psychiatrica Scandinavica · doi:10.1034/j.1600-0447.108.s417.7.x · Cited by 69
Metadata
- Authors
- Connor, K. M., Davidson, J. R. T., Potts, N. L. S., Tupler, L. A., Miner, C. M., Malik, M. L., Book, S. W., Colket, J. T., & Ferrell, F.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1998-10
- Volume
- 18
- Issue
- 5
- Pages
- 373-378
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2094859647
- Cited by
- 64
- References
- 1
- FWCI
- 8.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Discontinuation of Clonazepam in the Treatment of Social Phobia. https://app.cochat.ai/papers/10.1097/00004714-199810000-00004
- The paper
- Connor, K. M., Davidson, J. R. T., Potts, N. L. S., Tupler, L. A., Miner, C. M., Malik, M. L., Book, S. W., Colket, J. T., & Ferrell, F. (1998). Discontinuation of Clonazepam in the Treatment of Social Phobia. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199810000-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.